AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 4Trial registry record – peer review not applicable
Interventional Study of Everolimus in Humans
An interventional study involving 4 participants aged 18 to 65 years examined the effects of Everolimus. The primary endpoint was the percentage of participants experiencing adverse events, but no results have been posted yet.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet shown in people
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Ongoing – no results yet
Why it matters
This study aims to monitor safety events related to Everolimus, which is important for understanding its tolerability in the specified population.
What this does not prove
No results are available, and the planned enrollment and endpoints do not provide findings on the study's success or implications.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 4 · actual enrolment
- Randomised
- Not applicable
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- people; ages from 18 Years to 65 Years; sex All
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
Supporting passages (17)
study phasePhase: Phase 4
study designStudy type: Interventional
subjectsParticipants: people; ages from 18 Years to 65 Years; sex All
sample sizeEnrollment: 4 participants (actual)
peer reviewedPublication date: unknown.
populationParticipants: people; ages from 18 Years to 65 Years; sex All
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
outcomeNo results are posted.
human efficacyNo results are posted.
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
randomizedAllocation: Not applicable
controlledIntervention model: Single group
primary endpointPrimary endpoints: Percentage of participants with adverse events (AEs), Serious AEs (SAEs) and AEs of special interest (AESI)
interventionInterventions: Everolimus
follow upFollow-up: From first dose of study treatment up to 56 weeks; Up to 52 weeks; From screening up to 56 weeks
sample size basisEnrollment: 4 participants (actual)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.